MaxCyte, Inc.
General ticker "MXCT" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $150.6M (TTM average)
MaxCyte, Inc. does not follow the US Stock Market performance with the rate: -7.2%.
Estimated limits based on current volatility of 5.4%: low 1.30$, high 1.45$
Factors to consider:
- Total employees count: 91 (-20.2%) as of 2025
- US accounted for 66.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Incurring losses, Growth failure, Acquisition/divestiture risks, Geopolitical risks, Capital raising
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.12$, 2.74$]
- 2026-12-31 to 2027-12-31 estimated range: [1.25$, 2.94$]
Financial Metrics affecting the MXCT estimates:
- Positive: with PPE of -3.9 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Industry inventory ratio change (median), % of 0.25 <= 0.28
- Positive: Investing cash flow per share per price, % of 15.63 > -0.60
- Positive: Shareholder equity ratio, % of 84.68 > 64.23
Short-term MXCT quotes
Long-term MXCT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $41.29MM | $38.63MM | $33.03MM |
| Operating Expenses | $89.59MM | $89.82MM | $78.31MM |
| Operating Income | $-48.30MM | $-51.20MM | $-45.28MM |
| Non-Operating Income | $10.38MM | $10.14MM | $0.66MM |
| R&D Expense | $23.82MM | $22.23MM | $20.82MM |
| Income(Loss) | $-37.92MM | $-41.05MM | $-44.63MM |
| Net Income(Loss)* | $-37.92MM | $-41.05MM | $-44.63MM |
| Stockholders Equity | $232.17MM | $206.25MM | $171.49MM |
| Inventory | $12.23MM | $8.91MM | $7.55MM |
| Assets | $268.27MM | $239.47MM | $202.51MM |
| Operating Cash Flow | $-21.69MM | $-27.61MM | $-34.41MM |
| Capital expenditure | $3.70MM | $1.65MM | $1.77MM |
| Investing Cash Flow | $54.98MM | $6.93MM | $25.93MM |
| Financing Cash Flow | $2.14MM | $2.06MM | $0.66MM |
| Earnings Per Share** | $-0.37 | $-0.39 | $-0.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.